TRANSFORMING
POWERFUL
PROINFLAMMATORY
BIOLOGY
INTO NOVEL THERAPIES FOR CANCER PATIENTS
Our VISION
Make in-body spaceship available to everyone.
Our MISSION
To develop nanotechnology that treats cancer patients effectively but with lowest toxicities.
Pioneering the Interleukin-12 prodrug Axis
Broad applicability of Red Arrow prodrug technology including:
Small peptide to antibody full chain
Cationic protein to anionic protein
Lead asset – RA001 – IND planned for 2025
Based on novel technologies developed by a pioneer of nanomedicine, Prof. Dr. Horacio Cabral from the University of Tokyo
Main Investors: The University of Tokyo Edge Capital (UTEC)
Our Science
News
- 2023/08
Red Arrow Therapeutics, Co., Ltd. has been recognized as one of the ‘Top 10 Most Promising Biotech Startups from Asia – 2023’ by Asia Business Outlook magazine in their July issue! This prestigious recognition validates our commitment to innovation and transformative solutions in cancer immunotherapy. Join us in celebrating this milestone achievement!
https://www.asiabusinessoutlook.com/asia-startups/vendor/red-arrow-therapeutics-a-beacon-of-hope-for-cancer-patients-cid-1369.html